EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the MAPK Pathway in Cancer

Sultan F Kadasah iD

International Journal of Molecular Sciences · 24.12.2025 · 27 (1) · 214

DOI: 10.3390/ijms27010214 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.12.2025. Verfasst von Sultan F Kadasah. Beteiligte Einrichtung: Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia. Hauptthemen laut MEDLINE: Neoplasms, MAP Kinase Signaling System, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mitogen-activated protein kinase (MAPK) signaling cascade is fundamental in regulating cellular proliferation and differentiation, cell survival and cell death via apoptosis. Disruption of the MAPK signaling cascade at any point can lead to the evasion of apoptosis and unchecked cell growth and proliferation, leading to oncogenesis. This narrative review describes MAPK pathway dysregulation, its therapeutic targets, and resistance mechanisms. The therapeutic targeting of the MAPK pathway is complex due to the dual context-dependent roles of several kinases in the signaling cascade. Despite the therapeutic effectiveness of MAPK inhibitors, cancer cells develop chemoresistance that needs to be targeted via bypassing (c-Jun N-terminal kinases) JNK, protein kinase AKT and (mammalian target of rapamycin) mTOR signaling cascades, pairing MAPK inhibitors with multiple immune agents and targeting the MAPK pathway downstream of (extracellular signal-regulated kinase) ERK to prevent its reactivation mechanisms using combination therapies, downstream signaling regulators and (Proteolysis Targeting Chimeras) PROTACs. Additionally, MAPK-mediated regulation of ferroptosis is a novel oncological therapeutic targeting strategy for controlling tumor progression. The inhibition of the RAF/MAPK pathway results in alteration of several key regulators of ferroptosis, including SLCA11, GSH, GPX4 and NCO4A, hence affecting lipid cellular iron concentration and lipid peroxidation. Emerging therapies targeting the MAPK pathway should be designed considering crosstalk, compensatory signaling mechanism activation, the role of ferroptosis and the impact of the tumor microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMAP Kinase Signaling SystemProtein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein KinasesHumansAnimalsMolecular Targeted TherapyFerroptosis

Stichwörter der Autor:innen

carcinogenesiscellcell proliferationmitogen-activated protein kinasestumor microenvironment

Substanzen

Protein Kinase InhibitorsAntineoplastic AgentsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Biology, Faculty of Science, University of Bisha, P.O. Box 551, Bisha 61922, Saudi Arabia.

ORCID-Profile: Sultan F Kadasah

Zitieren

APA

Kadasah, S. F. (2025). Targeting the MAPK Pathway in Cancer. International Journal of Molecular Sciences, 27(1), 214. https://doi.org/10.3390/ijms27010214

Vancouver

Kadasah SF. Targeting the MAPK Pathway in Cancer. International Journal of Molecular Sciences. 2025;27(1):214. doi:10.3390/ijms27010214

BibTeX
@article{Kadasah2025,
  author = {Kadasah, Sultan F},
  title = {Targeting the MAPK Pathway in Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {27},
  number = {1},
  pages = {214},
  doi = {10.3390/ijms27010214}
}
Kostenlos starten →